Cascadian Therapeutics Inc.
(NASDAQ : CASC)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Loading CASC News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.76%172.501.1%$711.75m
GILDGilead Sciences, Inc.
0.09%70.540.9%$695.99m
CELGCelgene Corporation
0.47%134.311.1%$649.60m
REGNRegeneron Pharmaceuticals, Inc.
-1.75%517.332.7%$572.31m
ALXNAlexion Pharmaceuticals, Inc.
-0.13%126.071.9%$521.18m
BIIBBiogen Inc.
-0.09%280.321.2%$500.23m
VRTXVertex Pharmaceuticals Incorporated
-1.50%133.501.9%$279.31m
INCYIncyte Corporation
0.48%136.282.6%$278.87m
CLVSClovis Oncology, Inc.
-1.84%95.0018.0%$249.90m
TSROTESARO, Inc.
-2.16%146.5314.7%$249.01m
ILMNIllumina, Inc.
1.25%185.283.5%$164.61m
BLUEBluebird Bio, Inc.
-5.49%112.0019.3%$162.00m
PBYIPuma Biotechnology, Inc.
1.22%87.5021.1%$145.68m
KITEKite Pharma, Inc.
7.09%100.6616.1%$139.56m
EXASExact Sciences Corporation
2.31%35.5126.3%$130.55m

Company Profile

Cascadian Therapeutics, Inc. is a clinical-stage biopharmaceutical company, engages in the development of therapeutic products for the treatment of cancer. Its lead product candidate ONT-380, is an orally active and selective small-molecule HER2 inhibitor. It also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Seattle, WA.,009M3C-E